Endocrinology, Vol 134, 1254-1262, Copyright © 1994 by Endocrine Society

ARTICLES

Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma

C Lassarre and M Binoux
Unite de Recherches sur la Regulation de la Croissance (U.142), Institut National de la Sante et de la Recherche Medicale, Hopital Saint Antoine, Paris, France.

In a variety of physio-pathological conditions, but also in the normal state, calcium-dependent serine protease(s) partially proteolyze proportions of circulating insulin-like growth factor binding protein-3 (IGFBP-3). This occurs without disrupting the 150-kilodalton (kDa) complexes in which IGFBP-3 carries of most of the IGF-I and IGF-II in serum. In this work we show that the 150-kDa complex is functionally altered during pregnancy, which is when the largest proportion of IGFBP- 3 is proteolyzed. After preincubation at 4 C with [125I]IGF-I or -II with or without 1 microgram unlabeled IGF-I or -II, pooled plasma samples were gel filtered at pH 7.4. Larger proportions of labeled IGFs were found in the 150-kDa complexes of the third trimester pregnancy plasma pool than in those of the normal plasma pool, suggesting increased binding capacity. Nevertheless, competitive binding experiments using [125I]IGF-I and -II and IGFBP-3 preparations from each of the plasma pools showed that the competitive potencies of IGF- II and especially IGF-I were lower in pregnancy IGFBP-3 than in normal IGFBP-3. Scatchard analysis revealed a 2-fold loss of affinity for IGF- II and a 10-fold loss for IGF-I compared with that for normal plasma IGFBP-3. In studies at 37 C of the kinetics of dissociation of [125I]IGF-I and -II bound to IGFBP-3, IGF-II was dissociated 6 times faster, and IGF-I 10 times faster from pregnancy plasma IGFBP-3 than from normal plasma IGFBP-3. After incubation of individual plasma samples at 37 C and gel filtration at room temperature (in the presence of EDTA), IGFs were assayed in the three circulating pools (150-kDa and 40-kDa complexes and free IGFs), revealing a redistribution of pregnancy plasma IGFs. The proportion of total IGF-I in free form was nearly three times greater in pregnancy than in normal plasma (11.4% vs. 4.1%, P < 0.005), whereas that of free IGF-II was slightly smaller (1.5% vs. 2%). In the 150-kDa complexes, the proportion of total IGF-I was significantly smaller in pregnancy than in normal plasma, and that of IGF-II was greater. In the 40-kDa complexes, the proportion of total IGF-II was significantly smaller. The mean ratios of molar concentrations of free IGF-I/IGF-II were 0.43 in normal plasma and 2.23 in pregnancy plasma (P < 0.005).(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				N. Wilczak, J. W. Elting, D. Chesik, I. P. Kema, and J. De Keyser Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1 Stroke, September 1, 2006; 37(9): 2368 - 2371. [Abstract] [Full Text] [PDF]

				R. Cozzi, R. Attanasio, and M. Barausse Pregnancy in acromegaly: a one-center experience. Eur. J. Endocrinol., August 1, 2006; 155(2): 279 - 284. [Abstract] [Full Text] [PDF]

				A. V. Moller, S. P. Jorgensen, J.-W. Chen, A. Larnkjaer, T. Ledet, A. Flyvbjerg, and J. Frystyk Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur. J. Endocrinol., August 1, 2006; 155(2): 297 - 305. [Abstract] [Full Text] [PDF]

				D. R. Clemmons, M. Sleevi, and W. H. Busby Jr. Recombinant, Nonglycosylated Human Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) Is Degraded Preferentially after Administration to Type II Diabetics, Resulting in Increased Endogenous Glycosylated IGFBP-3 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6561 - 6568. [Abstract] [Full Text] [PDF]

				C. Fernandez-Tornero, R. M. Lozano, G. Rivas, M. A. Jimenez, L. Standker, D. Diaz-Gonzalez, W.-G. Forssmann, P. Cuevas, A. Romero, and G. Gimenez-Gallego Synthesis of the Blood Circulating C-terminal Fragment of Insulin-like Growth Factor (IGF)-binding Protein-4 in Its Native Conformation: CRYSTALLIZATION, HEPARIN AND IGF BINDING, AND OSTEOGENIC ACTIVITY J. Biol. Chem., May 13, 2005; 280(19): 18899 - 18907. [Abstract] [Full Text] [PDF]

				D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF]

				L. D. Payet, S. M. Firth, and R. C. Baxter The Role of the Acid-Labile Subunit in Regulating Insulin-Like Growth Factor Transport across Human Umbilical Vein Endothelial Cell Monolayers J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2382 - 2389. [Abstract] [Full Text] [PDF]

				H. G. Skinner, D. S. Michaud, G. A. Colditz, E. L. Giovannucci, M. J. Stampfer, W. C. Willett, and C. S. Fuchs Parity, Reproductive Factors, and the Risk of Pancreatic Cancer in Women Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 433 - 438. [Abstract] [Full Text] [PDF]

				R. C. Baxter What Is the Significance of IGF-Binding Protein-3 Proteolysis in the Circulation? J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5087 - 5088. [Full Text] [PDF]

				M. Binoux Tools Now Exist to Measure Circulating IGF-Binding Protein-3 Proteolysis, to Study Its Regulation and Its Effects on IGF-I Bioavailability J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5088 - 5089. [Full Text] [PDF]

				C. Lassarre, F. Duron, and M. Binoux Use of the Ligand Immunofunctional Assay for Human Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) to Analyze IGFBP-3 Proteolysis and IGF-I Bioavailability in Healthy Adults, GH-Deficient and Acromegalic Patients, and Diabetics J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1942 - 1952. [Abstract] [Full Text]

				F. F. LAUSZUS, J. G. KLEBE, and A. FLYVBJERG Macrosomia Associated With Maternal Serum Insulin-Like Growth Factor-I and -II in Diabetic Pregnancy Obstet. Gynecol., May 1, 2001; 97(5): 734 - 741. [Abstract] [Full Text] [PDF]

				C. LASSARRE and M. BINOUX Measurement of Intact Insulin-Like Growth Factor-Binding Protein-3 in Human Plasma Using a Ligand Immunofunctional Assay J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1260 - 1266. [Abstract] [Full Text]

				D. Byun, S. Mohan, M. Yoo, C. Sexton, D. J. Baylink, and X. Qin Pregnancy-Associated Plasma Protein-A Accounts for the Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Proteolytic Activity in Human Pregnancy Serum and Enhances the Mitogenic Activity of IGF by Degrading IGFBP-4 in Vitro J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 847 - 854. [Abstract] [Full Text]

				C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]

				S. I. Helle, T. Ueland, D. Ekse, S. S. Frøland, J. M. P. Holly, P. E. Lønning, and P. Aukrust The Insulin-Like Growth Factor System in Human Immunodeficiency Virus Infection: Relations to Immunological Parameters, Disease Progression, and Antiretroviral Therapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 227 - 233. [Abstract] [Full Text]

				R. C. Baxter Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976. [Abstract] [Full Text] [PDF]

				A. Halhali, A. R. Tovar, N. Torres, H. Bourges, M. Garabedian, and F. Larrea Preeclampsia Is Associated with Low Circulating Levels of Insulin-Like Growth Factor I and 1,25-Dihydroxyvitamin D in Maternal and Umbilical Cord Compartments J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1828 - 1833. [Abstract] [Full Text]

				D. C. Martin, J. L. Fowlkes, B. Babic, and R. Khokha Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor TIMP-1 J. Cell Biol., August 23, 1999; 146(4): 881 - 892. [Abstract] [Full Text] [PDF]

				P. Bang, J. Nygren, C. Carlsson-Skwirut, A. Thorell, and O. Ljungqvist Postoperative Induction of Insulin-Like Growth Factor Binding Protein-3 Proteolytic Activity: Relation to Insulin and Insulin Sensitivity J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2509 - 2515. [Abstract] [Full Text]

				C. Skjærbæk, A. Kaal, J. Møller, N. Vahl, J. Weeke, H. Ørskov, and A. Flyvbjerg No Effect of Growth Hormone on Serum Insulin-Like Growth Factor Binding Protein-3 Proteolysis J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1206 - 1210. [Abstract] [Full Text]

				B. Kubler, S. Cowell, J. Zapf, and T. Braulke Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum Endocrinology, April 1, 1998; 139(4): 1556 - 1563. [Abstract] [Full Text] [PDF]

				A. Sohlstrom, A. Katsman, K. L. Kind, C. T. Roberts, P. C. Owens, J. S. Robinson, and J. A. Owens Food restriction alters pregnancy-associated changes in IGF and IGFBP in the guinea pig Am J Physiol Endocrinol Metab, March 1, 1998; 274(3): E410 - E416. [Abstract] [Full Text] [PDF]

				Y. Yamanaka, E. M. Wilson, R. G. Rosenfeld, and Y. Oh Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins J. Biol. Chem., December 5, 1997; 272(49): 30729 - 30734. [Abstract] [Full Text] [PDF]

				P. Bang and P. J. Fielder Human Pregnancy Serum Contains at Least Two Distinct Proteolytic Activities with the Ability To Degrade Insulin-Like Growth Factor Binding Protein-3 Endocrinology, September 1, 1997; 138(9): 3912 - 3917. [Abstract] [Full Text] [PDF]

				Q. Zhang, M. Tally, O. Larsson, R. T. Kennedy, L. Huang, K. Hall, and P.-O. Berggren Insulin-like growth factor II signaling through the insulin-like growth factor II/mannose-6-phosphate receptor promotes exocytosis in insulin-secreting cells PNAS, June 10, 1997; 94(12): 6232 - 6237. [Abstract] [Full Text] [PDF]

				K. Sakai, W. H. Busby Jr., J. B. Clarke, and D. R. Clemmons Tissue Transglutaminase Facilitates the Polymerization of Insulin-like Growth Factor-binding Protein-1 (IGFBP-1) and Leads to Loss of IGFBP-1's Ability to Inhibit Insulin-like Growth Factor-I-stimulated Protein Synthesis J. Biol. Chem., March 16, 2001; 276(12): 8740 - 8745. [Abstract] [Full Text] [PDF]